Your browser does not support iframes.
Regional Stocks
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
Amarin Corp Plc
(NQ:
AMRN
)
6.770
USD
-0.150 (-2.17%)
Streaming Delayed Price
/ Updated:
10:15 AM EDT, May 24, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Intraday
1 Week
1 Month
3 Month
1 Year
Compare to:
None
S&P 500
Nasdaq
NYSE
AMEX
Russell 2000
Basic Materials
Conglomerates
Consumer Goods
Financial
Healthcare
Industrial Goods
Services
Technology
Utilities
Volume
673,801
Open
6.840
Bid (Size)
6.770 (800)
Ask (Size)
6.780 (1100)
Prev. Close
6.920
Today's Range
6.740 - 6.900
52wk Range
6.340 - 15.96
Shares Outstanding
150,312,023
Dividend Yield
N/A
Top News
More News
Amarin Stays Rangebound, Prescriptions Stagnate
May 23, 2013
Amarin Corporation (NASDAQ: AMRN) has been struggling a lot lately as retail channel prescription data for its EPA capsule Vascepa imply that the drug is starting to slow down its momentum in the...
Read More
category
AMRN
,
Bio/Wire
from
Bio-Wire.Com
29.3% Return Seen to Date on SmarTrend Amarin Call (AMRN)
May 23, 2013
from
Comtex SmarTrend® News Briefs
More News
Read More
Amarin Corporation (AMRN) gains on patent news
May 22, 2013
from
BAYSTREET RSS FEED
8 Biotechnology Stocks to Sell Now
May 22, 2013
category
NASDAQ:TSRX
,
NASDAQ:ACHN
,
NASDAQ:EXEL
, and 6 more.
from
InvestorPlace - Latest Headlines
Amarin Receive Patent Allowance for Combination Product of Vascepa and Statin Therapy
May 22, 2013
category
Contracts
,
Management
,
Benzinga
, and 4 more.
from
Latest Articles from Benzinga.com
Amarin Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa(R) and Statin Therapy
May 22, 2013
from
GlobeNewswire News Releases
StockCall Pre-Market Review on AMRN, ARAY, ATRS, and ANTH
May 20, 2013
from
ACCESSWIRE
Amarin's (AMRN) Vascepa Not in FDA Orange Book for April
May 17, 2013
from
StreetInsider.com News Articles
Trading Analysis for Amarin Corporation (AMRN)
May 17, 2013
from
AVAFIN
7 Biotechnology Stocks to Sell Now
May 15, 2013
category
NASDAQ:TSRX
,
NASDAQ:ACHN
,
NASDAQ:EXEL
, and 5 more.
from
InvestorPlace - Latest Headlines
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here
Your browser does not support iframes.